Precise estimates were not feasible, such as high odds ratio and wide confidence intervals that include the one (the null hypothesis value) observed when evaluating associations between MetS and KRAS status in non recto-sigmoid cancers. The gene discussed is KRAS; the disease is metabolic syndrome.